[HTML][HTML] A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas
Several editions of the World Health Organization (WHO) classifications of lympho-
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …
[HTML][HTML] Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies
Chronic lymphocytic leukemia is a well-defined lymphoid neoplasm with very
heterogeneous biological and clinical behavior. The last decade has been remarkably …
heterogeneous biological and clinical behavior. The last decade has been remarkably …
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Genomic profiling for clinical decision making in lymphoid neoplasms
L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
JF Seymour, TJ Kipps, BF Eichhorst… - Blood, The Journal …, 2022 - ashpublications.org
Abstract The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab
Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory …
Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory …
Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the …
PURPOSE In previous analyses of the MURANO study, fixed-duration venetoclax plus
rituximab (VenR) resulted in improved progression-free survival (PFS) compared with …
rituximab (VenR) resulted in improved progression-free survival (PFS) compared with …
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world
with an incidence of 4.2/100 000/year. The incidence increases to more than 30/100 …
with an incidence of 4.2/100 000/year. The incidence increases to more than 30/100 …
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology
WG Wierda, JC Byrd, JS Abramson, SF Bilgrami… - Journal of the National …, 2020 - jnccn.org
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are
characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone …
characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone …
Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model
PURPOSE Randomized trials established the superiority of ibrutinib-based therapy over
chemoimmunotherapy in chronic lymphocytic leukemia. Durability of progression-free …
chemoimmunotherapy in chronic lymphocytic leukemia. Durability of progression-free …
Guiding the global evolution of cytogenetic testing for hematologic malignancies
Cytogenetics has long represented a critical component in the clinical evaluation of
hematologic malignancies. Chromosome banding studies provide a simultaneous snapshot …
hematologic malignancies. Chromosome banding studies provide a simultaneous snapshot …